Research programme: purinoceptor P2Z antagonists - Affectis/Merck Serono

Drug Profile

Research programme: purinoceptor P2Z antagonists - Affectis/Merck Serono

Alternative Names: AFC-5128; AFC-5261

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affectis Pharmaceuticals
  • Developer Affectis Pharmaceuticals; Charcot-Marie-Tooth Association; Merck Serono
  • Class
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Charcot-Marie-Tooth disease
  • No development reported Multiple sclerosis; Neuropathic pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Germany (PO)
  • 21 Oct 2015 Preclinical development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top